ApoCell and Reata initiate Phase II diabetic renal disease trial
ApoCell develops assays for biomarker expression in circulating tumor and endothelial cells (CTC and CEC). Among other objectives, the RTA 402 diabetic nephropathy study seeks to isolate and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.